Evidence map›Paper›PMID 37894681›Full record

ReviewMolecules (Basel, Switzerland)2023

The Advancement of Nanomaterials for the Detection of Hepatitis B Virus and Hepatitis C Virus.

Wanting Shi, Kang Li, Yonghong Zhang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wanting ShiInterventional Therapy Center of Liver Disease, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China.
Kang LiBiomedical Information Center, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China.
Yonghong ZhangInterventional Therapy Center of Liver Disease, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China.
Beijing YouAn Hospital · CNCapital Medical University · CN

Funding

Beijing Hospitals Authority Youth Programme QML20211709Beijing Key Laboratory BZ0373Beijing Municipal Science & Technology Commission (Z171100001017078Capital's Funds of Health Improvement and Research CFH2020-1-2182National Key R&D Program of China 2020YFE0202400
6 · The paper itself

Abstract

Viral hepatitis is a global health concern mostly caused by hepatitis B virus (HBV) and hepatitis C virus (HCV). The late diagnosis and delayed treatment of HBV and HCV infections can cause irreversible liver damage and the occurrence of cirrhosis and hepatocellular carcinoma. Detecting the presence and activity of HBV and HCV is the cornerstone of the diagnosis and management of related diseases. However, the traditional method shows limitations. The utilization of nanomaterials has been of great significance in the advancement of virus detection technologies due to their unique mechanical, electrical, and optical properties. Here, we categorized and illustrated the novel approaches used for the diagnosis of HBV and HCV.

Indexed as

Carcinoma, HepatocellularHepatitis BHepatitis CLiver NeoplasmsNanostructuresHepacivirusHepatitis B virusHumansdetectionhepatitis B virus (HBV)hepatitis C virus (HCV)nanomaterials

Identifiers

PMID37894681
PMCPMC10608909
OpenAlexW4387843784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.